Linker technology in antibody-drug conjugates for cancer treatment

Research output: Contribution to journalArticle

Abstract

Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.

Original languageEnglish
Pages (from-to)406-411
Number of pages6
JournalDrug Delivery System
Volume28
Issue number5
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • Antibody-drug conjugate
  • Diketopiperazine
  • Linker
  • Spacer
  • Specifier

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Linker technology in antibody-drug conjugates for cancer treatment'. Together they form a unique fingerprint.

  • Cite this